Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25% Compared to Placebo in Subjects With Dry Eye

NCT05109702 is registered in ClinicalTrials.gov with HanAll BioPharma Co., Ltd. as lead sponsor.

NCT NCT05109702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05109702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25% Compared to Placebo in Subjects With Dry Eye
Lead sponsor
HanAll BioPharma Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
November 18, 2021
Completion date
May 6, 2022
Enrollment
260 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye